1-4 of 4
Shuchi S. Pandya
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial

Ingo K. Mellinghoff, Marta Penas-Prado, Katherine B. Peters, Howard A. Burris, III, Elizabeth A. Maher, Filip Janku, Gregory M. Cote, Macarena I. de la Fuente, Jennifer L. Clarke, Benjamin M. Ellingson, Saewon Chun, Robert J. Young, Hua Liu, Sung Choe, Min Lu, Kha Le, Islam Hassan, Lori Steelman, Shuchi S. Pandya, Timothy F. Cloughesy, Patrick Y. Wen
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (16): 4491–4499.
https://doi.org/10.1158/1078-0432.CCR-21-0611
Published: 15 August 2021
View article titled, Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial
Open the PDF for Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial in another window
Includes: Supplementary data
Journal Articles

The DART Study: Results from the Dose-Escalation and Expansion Cohorts Evaluating the Combination of Dalantercept plus Axitinib in Advanced Renal Cell Carcinoma

Martin H. Voss, Rupal S. Bhatt, Elizabeth R. Plimack, Brian I. Rini, Robert S. Alter, J. Thaddeus Beck, Dawn Wilson, Xiaosha Zhang, Musa Mutyaba, Chad Glasser, Kenneth M. Attie, Matthew L. Sherman, Shuchi S. Pandya, Michael B. Atkins
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (14): 3557–3565.
https://doi.org/10.1158/1078-0432.CCR-16-2395
Published: 13 July 2017
View article titled, The DART Study: Results from the Dose-Escalation and Expansion Cohorts Evaluating the Combination of Dalantercept plus Axitinib in Advanced Renal Cell Carcinoma
Open the PDF for The DART Study: Results from the Dose-Escalation and Expansion Cohorts Evaluating the Combination of Dalantercept plus Axitinib in Advanced Renal Cell Carcinoma in another window
Includes: Supplementary data
Journal Articles

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors

Geoffrey I. Shapiro, Jordi Rodon, Cynthia Bedell, Eunice L. Kwak, Jose Baselga, Irene Braña, Shuchi S. Pandya, Christian Scheffold, A. Douglas Laird, Linh T. Nguyen, Yi Xu, Coumaran Egile, Gerald Edelman
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2014) 20 (1): 233–245.
https://doi.org/10.1158/1078-0432.CCR-13-1777
Published: 05 January 2014
View article titled, Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors
Open the PDF for Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of ENMD-2076, a Novel Angiogenic and Aurora Kinase Inhibitor,in Patients with Advanced Solid Tumors

Jennifer R. Diamond, Bruno R. Bastos, Ryan J. Hansen, Daniel L. Gustafson, S. Gail Eckhardt, Eunice L. Kwak, Shuchi S. Pandya, Graham C. Fletcher, Todd M. Pitts, Gillian N. Kulikowski, Mark Morrow, Jamie Arnott, Mark R. Bray, Carolyn Sidor, Wells Messersmith, Geoffrey I. Shapiro
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (4): 849–860.
https://doi.org/10.1158/1078-0432.CCR-10-2144
Published: 15 February 2011
View article titled, Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of ENMD-2076, a Novel Angiogenic and Aurora Kinase Inhibitor,in Patients with Advanced Solid Tumors
Open the PDF for Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of ENMD-2076, a Novel Angiogenic and Aurora Kinase Inhibitor,in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data